Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy Designation Key aspects of a ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today ...

Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression ...

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...

Vabysmo now covered across all three approved indications in the province, giving patients a comprehensively funded option for their needs MISSISSAUGA, ON, Nov. 4, 2025 /CNW/ ...

A global analysis of 125 turmeric supplements across five major markets revealed widespread inconsistencies in labeling, ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

Qure (QURE) shares drop after FDA questions AMT-130 data for Huntington’s disease, delaying BLA submission. Read more here.

According to the latest analysis by DataM Intelligence, the Next-Generation Multiple Myeloma Therapies Market Size was valued ...

A malaria test commonly used across Asia and South America “is not fit for purpose”, researchers have claimed.